Cargando…

Development and validation of a radiomic signature to predict HPV (p16) status from standard CT imaging: a multicenter study

OBJECTIVES: Human papillomavirus (HPV) positive oropharyngeal cancer (oropharyngeal squamous cell carcinoma, OPSCC) is biologically and clinically different from HPV negative OPSCC. Here, we evaluate the use of a radiomic approach to identify the HPV status of OPSCC. METHODS: Four independent cohort...

Descripción completa

Detalles Bibliográficos
Autores principales: Leijenaar, Ralph TH, Bogowicz, Marta, Jochems, Arthur, Hoebers, Frank JP, Wesseling, Frederik WR, Huang, Sophie H, Chan, Biu, Waldron, John N, O'Sullivan, Brian, Rietveld, Derek, Leemans, C Rene, Brakenhoff, Ruud H, Riesterer, Oliver, Tanadini-Lang, Stephanie, Guckenberger, Matthias, Ikenberg, Kristian, Lambin, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The British Institute of Radiology. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223271/
https://www.ncbi.nlm.nih.gov/pubmed/29451412
http://dx.doi.org/10.1259/bjr.20170498
_version_ 1783369380720017408
author Leijenaar, Ralph TH
Bogowicz, Marta
Jochems, Arthur
Hoebers, Frank JP
Wesseling, Frederik WR
Huang, Sophie H
Chan, Biu
Waldron, John N
O'Sullivan, Brian
Rietveld, Derek
Leemans, C Rene
Brakenhoff, Ruud H
Riesterer, Oliver
Tanadini-Lang, Stephanie
Guckenberger, Matthias
Ikenberg, Kristian
Lambin, Philippe
author_facet Leijenaar, Ralph TH
Bogowicz, Marta
Jochems, Arthur
Hoebers, Frank JP
Wesseling, Frederik WR
Huang, Sophie H
Chan, Biu
Waldron, John N
O'Sullivan, Brian
Rietveld, Derek
Leemans, C Rene
Brakenhoff, Ruud H
Riesterer, Oliver
Tanadini-Lang, Stephanie
Guckenberger, Matthias
Ikenberg, Kristian
Lambin, Philippe
author_sort Leijenaar, Ralph TH
collection PubMed
description OBJECTIVES: Human papillomavirus (HPV) positive oropharyngeal cancer (oropharyngeal squamous cell carcinoma, OPSCC) is biologically and clinically different from HPV negative OPSCC. Here, we evaluate the use of a radiomic approach to identify the HPV status of OPSCC. METHODS: Four independent cohorts, totaling 778 OPSCC patients with HPV determined by p16 were collected. We randomly assigned 80% of all data for model training (N = 628) and 20% for validation (N = 150). On the pre-treatment CT images, 902 radiomic features were calculated from the gross tumor volume. Multivariable modeling was performed using least absolute shrinkage and selection operator. To assess the impact of CT artifacts in predicting HPV (p16), a model was developed on all training data (M(all)) and on the artifact-free subset of training data (M(no art)). Models were validated on all validation data (V(all)), and the subgroups with (V(art)) and without (V(no art)) artifacts. Kaplan–Meier survival analysis was performed to compare HPV status based on p16 and radiomic model predictions. RESULTS: The area under the receiver operator curve for M(all) and M(no art) ranged between 0.70 and 0.80 and was not significantly different for all validation data sets. There was a consistent and significant split between survival curves with HPV status determined by p16 [p = 0.007; hazard ratio (HR): 0.46], M(all) (p = 0.036; HR: 0.55) and M(no art) (p = 0.027; HR: 0.49). CONCLUSION: This study provides proof of concept that molecular information can be derived from standard medical images and shows potential for radiomics as imaging biomarker of HPV status. ADVANCES IN KNOWLEDGE: Radiomics has the potential to identify clinically relevant molecular phenotypes.
format Online
Article
Text
id pubmed-6223271
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher The British Institute of Radiology.
record_format MEDLINE/PubMed
spelling pubmed-62232712019-06-01 Development and validation of a radiomic signature to predict HPV (p16) status from standard CT imaging: a multicenter study Leijenaar, Ralph TH Bogowicz, Marta Jochems, Arthur Hoebers, Frank JP Wesseling, Frederik WR Huang, Sophie H Chan, Biu Waldron, John N O'Sullivan, Brian Rietveld, Derek Leemans, C Rene Brakenhoff, Ruud H Riesterer, Oliver Tanadini-Lang, Stephanie Guckenberger, Matthias Ikenberg, Kristian Lambin, Philippe Br J Radiol Full Paper OBJECTIVES: Human papillomavirus (HPV) positive oropharyngeal cancer (oropharyngeal squamous cell carcinoma, OPSCC) is biologically and clinically different from HPV negative OPSCC. Here, we evaluate the use of a radiomic approach to identify the HPV status of OPSCC. METHODS: Four independent cohorts, totaling 778 OPSCC patients with HPV determined by p16 were collected. We randomly assigned 80% of all data for model training (N = 628) and 20% for validation (N = 150). On the pre-treatment CT images, 902 radiomic features were calculated from the gross tumor volume. Multivariable modeling was performed using least absolute shrinkage and selection operator. To assess the impact of CT artifacts in predicting HPV (p16), a model was developed on all training data (M(all)) and on the artifact-free subset of training data (M(no art)). Models were validated on all validation data (V(all)), and the subgroups with (V(art)) and without (V(no art)) artifacts. Kaplan–Meier survival analysis was performed to compare HPV status based on p16 and radiomic model predictions. RESULTS: The area under the receiver operator curve for M(all) and M(no art) ranged between 0.70 and 0.80 and was not significantly different for all validation data sets. There was a consistent and significant split between survival curves with HPV status determined by p16 [p = 0.007; hazard ratio (HR): 0.46], M(all) (p = 0.036; HR: 0.55) and M(no art) (p = 0.027; HR: 0.49). CONCLUSION: This study provides proof of concept that molecular information can be derived from standard medical images and shows potential for radiomics as imaging biomarker of HPV status. ADVANCES IN KNOWLEDGE: Radiomics has the potential to identify clinically relevant molecular phenotypes. The British Institute of Radiology. 2018-06 2018-03-21 /pmc/articles/PMC6223271/ /pubmed/29451412 http://dx.doi.org/10.1259/bjr.20170498 Text en © 2018 The Authors. Published by the British Institute of Radiology This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 Unported License http://creativecommons.org/licenses/by-nc/4.0/, which permits unrestricted non-commercial reuse, provided the original author and source are credited.
spellingShingle Full Paper
Leijenaar, Ralph TH
Bogowicz, Marta
Jochems, Arthur
Hoebers, Frank JP
Wesseling, Frederik WR
Huang, Sophie H
Chan, Biu
Waldron, John N
O'Sullivan, Brian
Rietveld, Derek
Leemans, C Rene
Brakenhoff, Ruud H
Riesterer, Oliver
Tanadini-Lang, Stephanie
Guckenberger, Matthias
Ikenberg, Kristian
Lambin, Philippe
Development and validation of a radiomic signature to predict HPV (p16) status from standard CT imaging: a multicenter study
title Development and validation of a radiomic signature to predict HPV (p16) status from standard CT imaging: a multicenter study
title_full Development and validation of a radiomic signature to predict HPV (p16) status from standard CT imaging: a multicenter study
title_fullStr Development and validation of a radiomic signature to predict HPV (p16) status from standard CT imaging: a multicenter study
title_full_unstemmed Development and validation of a radiomic signature to predict HPV (p16) status from standard CT imaging: a multicenter study
title_short Development and validation of a radiomic signature to predict HPV (p16) status from standard CT imaging: a multicenter study
title_sort development and validation of a radiomic signature to predict hpv (p16) status from standard ct imaging: a multicenter study
topic Full Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223271/
https://www.ncbi.nlm.nih.gov/pubmed/29451412
http://dx.doi.org/10.1259/bjr.20170498
work_keys_str_mv AT leijenaarralphth developmentandvalidationofaradiomicsignaturetopredicthpvp16statusfromstandardctimagingamulticenterstudy
AT bogowiczmarta developmentandvalidationofaradiomicsignaturetopredicthpvp16statusfromstandardctimagingamulticenterstudy
AT jochemsarthur developmentandvalidationofaradiomicsignaturetopredicthpvp16statusfromstandardctimagingamulticenterstudy
AT hoebersfrankjp developmentandvalidationofaradiomicsignaturetopredicthpvp16statusfromstandardctimagingamulticenterstudy
AT wesselingfrederikwr developmentandvalidationofaradiomicsignaturetopredicthpvp16statusfromstandardctimagingamulticenterstudy
AT huangsophieh developmentandvalidationofaradiomicsignaturetopredicthpvp16statusfromstandardctimagingamulticenterstudy
AT chanbiu developmentandvalidationofaradiomicsignaturetopredicthpvp16statusfromstandardctimagingamulticenterstudy
AT waldronjohnn developmentandvalidationofaradiomicsignaturetopredicthpvp16statusfromstandardctimagingamulticenterstudy
AT osullivanbrian developmentandvalidationofaradiomicsignaturetopredicthpvp16statusfromstandardctimagingamulticenterstudy
AT rietveldderek developmentandvalidationofaradiomicsignaturetopredicthpvp16statusfromstandardctimagingamulticenterstudy
AT leemanscrene developmentandvalidationofaradiomicsignaturetopredicthpvp16statusfromstandardctimagingamulticenterstudy
AT brakenhoffruudh developmentandvalidationofaradiomicsignaturetopredicthpvp16statusfromstandardctimagingamulticenterstudy
AT riestereroliver developmentandvalidationofaradiomicsignaturetopredicthpvp16statusfromstandardctimagingamulticenterstudy
AT tanadinilangstephanie developmentandvalidationofaradiomicsignaturetopredicthpvp16statusfromstandardctimagingamulticenterstudy
AT guckenbergermatthias developmentandvalidationofaradiomicsignaturetopredicthpvp16statusfromstandardctimagingamulticenterstudy
AT ikenbergkristian developmentandvalidationofaradiomicsignaturetopredicthpvp16statusfromstandardctimagingamulticenterstudy
AT lambinphilippe developmentandvalidationofaradiomicsignaturetopredicthpvp16statusfromstandardctimagingamulticenterstudy